PLYX · Polaryx Therapeutics, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2025 | FY2024 |
|---|---|---|
| $6.27M | $2.81M | |
| $1.56M | $1.54M | |
| $7.82M | $4.35M | |
| -$7.82M | -$4.35M | |
| -$8.99M | -$30.36M | |
| -$8.99M | -$30.36M | |
| USD/shares | -$0.20 | -$0.89 |
| USD/shares | -$0.20 | -$0.89 |
| shares | 45.42M | 34.2M |
| shares | 45.42M | 34.2M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 313 similar-size Biotechnology companies (of 532 listed).